Patent ID: 7268131

Claim:
A method of lowering and controlling intraocular pressure in an eye of a patient in need thereof, comprising administering to the patient a pharmaceutically effective amount of a compound of Formula I: wherein R 1 and R 2 are independently hydrogen or C 1-4 alkyl; R 3 is hydrogen or C 1-4 alkyl, or R 2 and R 3 together can complete a pyrrolidine or piperidine ring, which can be substituted with C 1-4 alkyl; R 4 is hydrogen, halogen, or C 1-4 alkyl; R 5 and R 6 are independently hydrogen, halogen, C 1-6 alkyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 1-6 alkylsulfoxide, nitrile, or C 1-6 alkyl substituted with halogen; R 7 is hydrogen, C═OR 9 , ═O, C 1-6 alkyl, or substituted C 1-6 alkyl wherein the substituent is at least one of hydroxyl, C 1-6 alkoxy, NR 12 R 13 , CO 2 H, CO 2 C 1-6 alkyl, C(═O)NR 12 R 13 , and a saturated or unsaturated 5 or 6-membered heteroaryl ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C 1-4 alkyl or phenyl; R 8 is hydrogen, C 1-6 alkyl, or substituted C 1-6 alkyl wherein the substituent is at least one of hydroxyl, C 1-6 alkoxy, NR 12 R 13 , CO 2 H, CO 2 C 1-6 alkyl, and C(═O)NR 12 R 13 ; R 9 is hydroxyl, C 1-6 alkoxy, NR 14 R 15 , C 1-6 alkyl, or substituted C 2-6 alkyl wherein the substituent is at least one of hydroxyl, C 1-6 alkoxy, NR 12 R 13 , CO 2 H, CO 2 C 1-6 alkyl, halogen, and a heterocyclic ring selected from pyrrolidine-2-yl, imidazo-2-yl, imidazo-4-yl, morpholine-3-yl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, which can be unsubstituted or substituted with C 1-4 alkyl; R 12 and R 13 are independently hydrogen, C 1-6 alkyl, or substituted C 2-6 alkyl wherein the substituent is at least one of hydroxyl, C 1-6 alkoxy, and halogen, or R 12 , R 13 , and the intervening nitrogen atom together can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C 1-4 alkyl or C 1-4 alkyl substituted with hydroxy or C 1-4 alkoxy; R 14 and R 15 are independently hydrogen, C 1-6 alkyl, hydroxyl, C 1-6 alkoxy, or substituted C 2-6 alkyl wherein the substituent is at least one of hydroxyl, C 1-6 alkoxy, halogen and a heterocyclic ring selected from pyrrolidine-2-yl, imidazo-2-yl, imidazo-4-yl, morpholine-3-yl, oxazolyl, isoxazolyl, thiazolyl, tetrazolyl, which can be unsubstituted or substituted with C 1-4 alkyl, or R 14 , R 15 , and the intervening nitrogen atom together can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C 1-4 alkyl or C 1-4 alkyl substituted with hydroxy or C 1-4 alkoxy; A is N or CH; X and Y are either N or C, provided that X and Y cannot be the same; and the dashed bonds denote a single or double bond; or a pharmaceutically acceptable salt thereof.